Results 131 to 140 of about 35,270 (248)

Extended Infusions of Meropenem for Febrile Neutropenia

, 2019
Background: Neutropenic fever is an oncologic emergency that requires quick intervention with anti-pseudomonal beta-lactam antibiotics, such as meropenem.
Reeves, PharmD, BCOP, David J, Przybylski, PharmD, Daniel J   +1 more
core  

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Follicular lymphoma (FL) is the most common indolent lymphoma. Although chemoimmunotherapy is effective, toxicity remains problematic, and novel treatments are required. We performed a Phase Ib/II study of obinutuzumab, lenalidomide, and venetoclax in patients with treatment‐naïve, high tumor burden, advanced‐stage FL. During induction (6 × 28‐
Chan Y. Cheah, Piers Blombery, Amanda Johnston, Joel Wight, Katharine L. Lewis, Rory Bennett, Jing Xie, Stella Vlachos, Sally M. Hunter, Joyce Gonzales, Sally Binks, John F. Seymour   +11 more
wiley   +1 more source

CACA guidelines for managing cancer therapy-induced neutropenia (2026)

Holistic Integrative Oncology
Anticancer therapy, encompassing systemic therapies such as chemotherapy, targeted therapy, and immunotherapy, as well as radiotherapy, can induce neutropenia.
Li Xiao, Fenghua Wang, Ying Yuan, Shu Xia, Wenxing Qin, Xiaotian Zhang, Yanhong Deng, Xianglin Yuan, Yi Ba, Jun Zhang, China Anti-Cancer Association Committee of Neoplastic Supportive-Care (CONS)   +10 more
doaj   +1 more source

Mean Platelet Volume-to-Albumin Ratio as a Predictor of Mortality in Patients with Febrile Neutropenia: An Observational Study

Medicina
Background and Objectives: Febrile neutropenia (FN) is a life-threatening complication in cancer patients, necessitating early risk stratification for optimal management.
Jelena Dimitrijević, Marina Čalamać, Ognjen Đurmez, Marko Stojanović   +3 more
doaj   +1 more source

Characteristics of US ED febrile neutropenia visits, 2006–2014.

, 2019
Characteristics of US ED febrile neutropenia visits, 2006–2014.
Christopher W. Baugh (344298), Emily L. Mueller (2155564), Mohammad Kamal Faridi (6729455), Daniel J. Pallin (367110), Carlos A. Camargo Jr. (485543)   +4 more
core   +1 more source

Use of antimicrobials during febrile neutropenia episodes (n = 515).

, 2019
Use of antimicrobials during febrile neutropenia episodes (n = 515).
Lucas F. De Candia (7610519), Oscar Bottasso (328465), Gervasio F. Sasia (7610516), Matias A. Gruvman (7610522), María S. Rodríguez (3030198), Mauro Tortolo (7610510), Alcides A. Greca (7610525), Roberto L. Parodi (7610504), Mariana Lagrutta (7610507), Estefanía Navall (7610513)   +9 more
core   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1334-1342, June 2026.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.
María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty   +10 more
wiley   +1 more source

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action.
Sebastian Grosicki, Habte Yimer, Rosa Ayala, Suning Chen, Hong Liu, Françoise Boyer, Paola Guglielmelli, Marco Brociner, Paolo Sportoletti, Gabor Mikala, Panagiotis Tsirigotis, Jin Zhang, Tomer Mark, Yi Chai, Andrea Ellero, Alessandro Lucchesi   +15 more
wiley   +1 more source

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Objective To retrospectively analyze the early efficacy and safety of azacitidine plus lisaftoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome with increased blasts (MDS‐IB), providing a reliable clinical reference.
Shan Meng, Wanhong Zhao, Hui Zhang, Bo Lei, Wanggang Zhang, Yilin Zhang, Jin Wang, Yinxia Chen, Xingmei Cao, Liufang Gu   +9 more
wiley   +1 more source